MET and gestational diabetes: Beyond emphasizing the proposed utility of HGF as potential therapeutic target in IR, this review also discussed how maternal β-cell adaptation, during pregnancy, depends on the HGF/c-Met signaling pathway, and that impairment of this pathway can lead to the onset of GDM.